Fuzheng Huayu
Phase 3Small molecule
Fuzheng Huayu is one of 35 small molecule programs targeting Hepatitis B. It is currently in Phase 3.
2
Indications
6
Total Trials
2
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
43 competitors in Hepatitis B
#DrugCompanyPhaseTrials
1Vemlidy
GileadApproved
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Emtriva
GileadApproved
Selzentry
GSKApproved
Epivir
GGlaxo Dba Glaxosmithkline
Approved
Sunlenca
GileadApproved
Cabenuva
GSKApproved
Sustiva
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Retrovir
BBp Consulting, Inc
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Hepatitis1 trial
Hepatitis B1 trial
1 more indication
Fatty Liver1 trial
Efficacy and Safety of Fuzheng Huayu Tablets in Patients With Metabolic Dysfunction-Associated Fatty Liver Cirrhosis (Compensated): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study
Not yet recruiting·XXinhua Hospital, Shanghai Jiao Tong University School of Medicine·Approved·NCT07663643·459 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fuzheng Huayu. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SShuGuang Hospital